close read more

The Servier Group

Committed to therapeutic progress to serve patient needs

Meet the healthcare challenges of tomorrow

Committed employees

Men and women proud to contribute to care for patients and save lives

Join our Group

Servier R&D

Meeting patient needs as effectively as possible

Accelerate therapeutic innovation

A local production

The agility of an integrated industrial model

Industrial excellence for a quality healthcare offering

Servier - Independent international pharmaceutical laboratory

logo twitter


countries in which
the Group’s medicines
are distributed
+ 20 %

of the brand-name revenue
in R&D every year

4.7 billion

euros in revenue in 2020/2021 comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.

4 therapeutic areas

cardiometabolism, neuroscience
and immuno-inflammation

icon play
icon play

Join our teams!

We do everything possible for all Group employees to have the means to succeed, to adapt, to take on responsibilities and to grow. At Servier, you will be offered a unique and meaningful professional experience.

Cholangiocarcinoma, a rare tumor of the bile duct

Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive tumor. It is often associated with medical antecedents such as cirrhosis or infections of the liver. Surgery is the only treatment to cure this form of cancer. Developments in immunotherapy and new targeted drug therapies bring greater hope and better quality of life for patients.

2022 Greetings

Servier wishes you a healthy and prosperous new year 2022.

The basis for our actions

Because passing on to future generations a world that can ensure access to quality health care for all is our vision for the future, at Servier, all over the world, we are ready to meet the health care challenges of tomorrow, for and with patients. Discover our corporate video.

icon play